Specimen:
Collect
- One SST
Also Acceptable:
- One Green Top (Li Heparin)
- One Green Top (Na Heparin)
- One Lavender (EDTA)
- One Pink Top (EDTA)
- One Red Top
Submit
- 1 mL (Min:0.5 mL) Serum . Submit Refrigerated. Submit in a Standard Transport Tube.
Also Acceptable:
- 1 mL (Min:0.5 mL) Plasma . Submit Refrigerated. Submit in a Standard Transport Tube.
Special Handling
- Allow specimen to clot completely at room temperature
- For patients receiving therapy with high biotin doses (>5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Stability
Ambient: 2 Hour(s); Refrigerated: 7 Day(s); Frozen: 6 Month(s); Incubated: Unacceptable
Methodology
- Electrochemiluminescence Immunoassay (ECLIA)
Performed
Mon-Fri
Reported
1-3 Day(s)
CPT Codes
- 82378
Interpretive Data
General Reference Range : 0-3.8 ng/ml
Reference Range for Smokers is 0-5.5 ng/mL
The Roche e801 CEA electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. Measurement of CEA has been shown to be clinically relevant in the management of patients with colorectal, breast, lung, prostatic, pancreatic, and ovarian carcinomas. The CEA assay value, regardless of level, should not be interpreted as evidence for the presence or absence of malignant disease and is not recommended for use as a screening procedure to detect the presence of cancer in the general population.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Reference Range for Smokers is 0-5.5 ng/mL
The Roche e801 CEA electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. Measurement of CEA has been shown to be clinically relevant in the management of patients with colorectal, breast, lung, prostatic, pancreatic, and ovarian carcinomas. The CEA assay value, regardless of level, should not be interpreted as evidence for the presence or absence of malignant disease and is not recommended for use as a screening procedure to detect the presence of cancer in the general population.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Components
- 2085 - CEA
Last Updated: January 20, 2025 @ 10:13 am
Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date. Updated test information can only be guaranteed by using this website.
